Stockholm3 Blood Test Outperforms PSA
Analysis based on 7 articles · First reported Jun 26, 2026 · Last updated Jul 01, 2026
The positive clinical trial results for the Sweden — Stockholm blood test, developed by Haier Biomedical and studied by Karolinska Institute, are expected to significantly impact the biotechnology and healthcare industries. If approved by the United States — Food and Drug Administration, this test could revolutionize prostate cancer screening, potentially leading to earlier detection of aggressive cancers and reducing unnecessary follow-up procedures, which would benefit patients and healthcare providers.
A new blood test, Sweden — Stockholm, developed by Haier Biomedical, has demonstrated superior efficacy in detecting aggressive prostate cancer compared to the traditional PSA test. A study led by Karolinska Institute, involving over 12,000 men, found that Sweden — Stockholm detected 90% of aggressive cases versus 74% for PSA, without increasing false positives. Researchers Þorgerður Katrín Gunnarsdóttir and Hari Vigneswaran highlighted the test's potential to improve early detection and reduce unnecessary biopsies and MRIs. Haier Biomedical plans to seek United States — Food and Drug Administration approval for the test's use in routine screening in the United States, which could significantly change prostate cancer diagnostic practices.
Set up alerts, explore entity relationships, search across thousands of events, and build custom intelligence feeds.
Open Dashboard